Infectious Disease
RSSArticles
-
Ombitasvir, Paritaprevir, and Ritonavir, Dasabuvir Tablets (Viekira™ Pak)
The FDA has approved the fourth new product for the treatment of chronic hepatitis C (HCV) infection since November 2013. The latest is a four fixed-drug combination (3-DAA) that includes paritaprevir, a nonstructure 3/4A protease inhibitor, ombitasvir, an inhibitor of the NS5A replication complex, and copackaged with dasabuvir, a nonnucleoside NS5B polymerase inhibitor. The plasma levels of paritaprevir is boosted with ritonavir, a CYP3A inhibitor to permit once-daily dosing. The combination is marketed by AbbVie, Inc. as Viekira Pak.
-
Can Intracardiac Echo Be Used as a Substitute for Transesophageal Echo Prior to Atrial Fibrillation Ablation?
This article originally appeared in the January 2015 issue of Clinical Cardiology Alert.
-
Should Metformin Use In Patients With Chronic Kidney Disease Be Expanded?
SYNOPSIS: Expansion of the metformin label to include patients with mild-to-moderate kidney disease is appropriate.
-
Nonsteroidal Anti-inflammatory Drug Use and Risk of Atrial Fibrillation
SYNOPSIS: Use of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with an increased risk of incident atrial fibrillation, especially among new users of NSAIDs.
-
Infectious Disease [ALERT] Updates
Treatment of C. Diff. — follow the guidelines. Semi roll-over causes Cryptosporidiosis Antibiotics prescribed from decision-fatigue? -
A New Expanded Human Papillomavirus Vaccine
The U.S. FDA approved a new human papillomavirus (HPV) vaccine in December of 2014.1 Two HPV vaccines have been available for several years — a bivalent vaccine (HP2) containing L1 protein of the oncogenic types 16 and 18 as well as a quadrivalent vaccine (HP4)containing type 16 and 18 together with types 6 and 11 (which cause genital warts). The Advisory Committee on Immunization Practices (ACIP) has recently updated their recommendations for the use of these vaccines:
-
Controlling the Spread of Chikungunya Virus: A New Possibility
SYNOPSIS: A phase-1 clinical trial of a virus-like particle (VLP)-based vaccine demonstrates safety, tolerability, and immunogenicity against rapidly spreading Chikungunya virus.
-
Antiviral Therapy Improves Outcomes in Immunocompromised but Not Immunocompetent HSV Meningitis Patients
SYNOPSIS: A retrospective, observational, single-center study found immunocompromised patients are at increased risk for neurologic sequelae from HSV meningitis and likely benefit from antiviral therapy. There is no benefit to antiviral therapy in immunocompetent individuals.
-
Reactive Hemophagocytic Syndrome in Adults
Patients with HPS were more likely to be immunosuppressed.
-
Peramivir for Treatment of Influenza
Peramivir (RapivabTM) was recently approved by the FDA for treating acute uncomplicated influenza.